← All trials
NCT05580341
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Oct 14, 2022
- Last posted
- Oct 28, 2022
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Zerun Biotechnology Co.,LtdLead sponsor
- Walvax Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.